Worldwide, giardiasis is one of the most widespread non-viral infections causing diarrhea in humans, infecting an estimated 200 million people each year.1
At any given time, it can affect anywhere from 2 to 5% of the population in developed countries and 20 to 30% of the population in developing countries.2
Anyone can get Giardia, but the disease is more common in areas without adequate sanitary conditions and those with outdated water treatment facilities. It is most common in tropical countries and among tourists and business travelers who visit developing countries.
In the United States, more than 20,000 cases of giardiasis were reported annually between 2003 and 2005.3 However, the true number of cases is probably much higher, because not every infected person seeks treatment.
The disease is more common during summer months, and it's more likely to strike children between the ages of 1 and 9 and adults aged 30 to 39.3 According to researchers, 7% of children ages 1 to 3, 11% of children entering day care, and up to 35% of children attending day care may be infected.1,2
- Learn more about giardiasis:
- Cause and Risk Factors»
- Signs and Symptoms»
- Tests and Diagnosis»
- Treatment of Giardiasis»
Important Safety Information
WARNING: POTENTIAL RISK FOR CARCINOGENICITY
Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Its use should be reserved for the conditions described in INDICATIONS AND USAGE.
Contraindications
- Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives
- First trimester of pregnancy
- Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose
Warnings and Precautions
- Seizures and neuropathy have been reported. Discontinue Tindamax if abnormal neurologic signs develop
- Vaginal candidiasis may develop with Tindamax and require treatment with an antifungal agent
- Use Tindamax with caution in patients with blood dyscrasias. Tindamax may produce transient leukopenia and neutropenia
Adverse Reactions
Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation. To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.
Please see full Prescribing Information
- Giardia: Drinking Water Fact Sheet [Internet]. United States Environmental Protection Agency, Office of Water; 2000 Sept [accessed 2008 Jul 10]. Available from: http://www.epa.gov/waterscience/criteria/humanhealth/microbial/giardiafs.pdf
- Ortega YR, Adam RD. Giardia: overview and update. Clin Infect Dis. 1997 Sep;25(3):545-9; quiz 550.
- Yoder JS, Beach MJ; Centers for Disease Control and Prevention (CDC). Giardiasis surveillance--United States, 2003-2005. MMWR Surveill Summ. 2007 Sep 7;56(7):11-8.
Websites
Only Tindamax® is approved to treat both bacterial vaginosis and trichomoniasis (TV).
Clinical Insight
Oral vs vaginal cream therapy: Patient preference for oral dosing is demonstrated to be 84%. More»
Beyond BV
Tindamax® may be prescribed for other infections including:
The Mission Pharmacal family of products
Learn more about innovative therapies including...
CitraNatal®Calcium citrate with vital nutrients for mother and baby » Ferralet® 90The iron therapy with biocomplementary absorption » Urocit®-KKidney stone therapy with wax-matrix delivery for slow, sustained release »
